SCHEMBL3854023

SCHEMBL3854023

COc1ccc([C](c2ccc(OC)cc2)c2ccco2)cc1

nearest known ligand 0.57

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 9/20 0.57
KMT2A Q03164 8/20 0.57
NPC1 O15118 4/20 0.57
MEN1 O00255 2/20 0.57
TSHR P16473 1/20 0.57
RAB9A P51151 3/20 0.56
SMN1; SMN2 Q16637 2/20 0.56
POLB P06746 2/20 0.56
PKM P14618 1/20 0.56
L3MBTL1 Q9Y468 1/20 0.56
MAPT P10636 3/20 0.52
KDM4E B2RXH2 2/20 0.52
HPGD P15428 2/20 0.52
AHR P35869 1/20 0.52
GAA P10253 1/20 0.52
CYP2C9 P11712 1/20 0.52
HTT P42858 1/20 0.52
RECQL P46063 1/20 0.52
HSD17B10 Q99714 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3853904 0.96 ALDH1A1 (0.57) ALDH1A1KMT2ANPC1MEN1TSHR
SCHEMBL3860533 0.95 KMT2A (0.54) ALDH1A1KMT2ANPC1MEN1TSHR
SCHEMBL28716282 0.82 ALDH1A1 (0.55) ALDH1A1KMT2ANPC1MEN1TSHR
SCHEMBL13142806 0.82 KMT2A (0.62) ALDH1A1KMT2ANPC1MEN1TSHR
SCHEMBL15988631 0.77 ALDH1A1 (0.68) ALDH1A1KMT2ANPC1MEN1TSHR
SCHEMBL10320585 0.77 ALDH1A1 (0.68) ALDH1A1KMT2ANPC1MEN1TSHR
SCHEMBL10724603 0.76 KMT2A (0.59) ALDH1A1KMT2ANPC1MEN1TSHR
SCHEMBL27884410 0.76 ALDH1A1 (0.56) ALDH1A1KMT2ANPC1MEN1TSHR
SCHEMBL41021 0.75 CA1 (0.65) ALDH1A1TSHRSMN1; SMN2MAPTKDM4E
SCHEMBL10724596 0.73 KMT2A (0.62) ALDH1A1KMT2ANPC1MEN1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7585970-B2 Method of polynucleotide synthesis using modified support AGILENT TECHNOLOGIES, INC. (US) 2009-09-08 US disclosed
US-7427679-B2 Precursors for two-step polynucleotide synthesis AGILENT TECHNOLOGIES, INC. (US) 2008-09-23 US disclosed
US-7417139-B2 Method for polynucleotide synthesis AGILENT TECHNOLOGIES, INC. (US) 2008-08-26 US disclosed
US-7385050-B2 Cleavable linker for polynucleotide synthesis AGILENT TECHNOLOGIES, INC. (US) 2008-06-10 US disclosed
US-7193077-B2 Exocyclic amine triaryl methyl protecting groups in two-step polynucleotide synthesis AGILENT TECHNOLOGIES, INC. (US) 2007-03-20 US disclosed
US-20050186580-A1 Quality control method for array manufacture AGILENT TECHNOLOGIES, INC. 2005-08-25 US disclosed
US-20050186579-A1 MALDI-MS analysis of nucleic acids bound to a surface AGILENT TECHNOLOGIES, INC. 2005-08-25 US disclosed
EP-1512691-A1 Protecting groups for two-step polynucleotide synthesis Agilent Technologies Inc (US) 2005-03-09 EP disclosed
US-20050048496-A1 Method of polynucleotide synthesis using modified support AGILENT TECHNOLOGIES, INC. 2005-03-03 US disclosed
US-20050048601-A1 Method for polynucleotide synthesis REGENTS OF THE UNIVERSITY OF COLORADO, THE 2005-03-03 US disclosed
US-20050049411-A1 Exocyclic amine triaryl methyl protecting groups in two step polynucleotide synthesis REGENTS OF THE UNIVERSITY OF COLORADO, THE 2005-03-03 US disclosed
US-20050048497-A1 Cleavable linker for polynucleotide synthesis THE REGENTS OF THE UNIVERSITY OF COLORADO 2005-03-03 US disclosed
US-20050049407-A1 Precursors for two-step polynucleotide synthesis THE REGENTS OF THE UNIVERSITY OF COLORADO 2005-03-03 US disclosed
EP-1510522-A1 Method of polynucleotide synthesis using modified support Agilent Technologies Inc (US) 2005-03-02 EP disclosed
EP-1510523-A1 Precurors for two-step polynucleotide synthesis Agilent Technologies Inc (US) 2005-03-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050048496-A1 Method of polynucleotide synthesis using modified support POLN, POLRMT, POLM ALDH1A1 4090/4885KMT2A 2545/4885NPC1 3253/4885
US-20050048601-A1 Method for polynucleotide synthesis POLN, RNGTT, NSUN2 ALDH1A1 4398/4885KMT2A 1288/4885NPC1 2946/4885
US-20050049407-A1 Precursors for two-step polynucleotide synthesis NT5C3B, NSUN2, POLN ALDH1A1 4145/4885KMT2A 1355/4885NPC1 2647/4885
US-20050048497-A1 Cleavable linker for polynucleotide synthesis TYMP, POLN, CPSF1 ALDH1A1 4036/4885KMT2A 3824/4885NPC1 3839/4885
US-20050049411-A1 Exocyclic amine triaryl methyl protecting groups in two step polynucleotide synthesis NT5C3B, RNMT, NSUN2 ALDH1A1 4399/4885KMT2A 909/4885NPC1 2521/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.